Noxopharm receives $1.4 million R&D tax incentive rebate

Highlights

- **$1.4 million refund received via Australian Government R&D Tax Incentive scheme**
- **Support for SOF-SKN™ extension study and Sofra™ technology platform**

Sydney, 12 November 2026: Australian clinical-stage biotechnology company **Noxopharm Limited (ASX:NOX)** has received a $1,422,471 rebate under the Australian Government's Research and Development Tax Incentive scheme for expenditure during FY 2026.

The rebate will support the upcoming SOF-SKN™ extension study in patients with cutaneous lupus erythematosus (CLE), as well as the Sofra™ technology platform more generally.

The study is designed to assess the safety and tolerability of SOF-SKN in patients with CLE, also known as skin lupus, and generate initial signals of clinical efficacy.

Lupus is an autoimmune disease that can affect different organs, and CLE is a sub-type of lupus that manifests in the skin. There are currently no therapies specifically approved for treating CLE, and there is a significant unmet need for targeted and well-tolerated therapies.

The global CLE treatment market was valued at US$5.4 billion in 2024. There is also an option to expand SOF-SKN into adjacent inflammatory autoimmune skin disease including psoriasis, dermatomyositis and rosacea. The broader Sofra technology platform is also being explored across other diseases associated with immune-system dysregulation, including cancer.

Noxopharm CEO Dr Olivier Laczka has approved the release of this document to the market on behalf of the Board of Directors.

-ENDS-

About the Sofra™ technology platform

Developed from a breakthrough discovery in innate immunology, the Sofra technology platform represents a revolutionary approach to drug design by translating a new understanding of innate biology into targeted therapeutics that enable precision control of disease-relevant signalling.

Sofra is based on the use of synthetic nucleic acids, known as oligonucleotides, to mimic natural regulators of the body's defence system.

This novel approach enables selective and modular tuning of immune sensors, reducing or stimulating their associated biological responses to mitigate a broad range of diseases and enhance RNA-based therapies and emerging therapeutic technologies.

Sofra is focused on inflammatory and autoimmune diseases such as rheumatoid arthritis, lupus and diabetes, as well as immuno-oncology for cancer treatment. The global autoimmune disease

therapeutics market was worth US$163.2 billion in 2024 and is expected to reach US$219.6 billion by 2035, while the worldwide immuno-oncology market was US$43 billion in 2023 and is projected to hit US$284 billion by 2033.

Further information and animations: SOF-SKN / SOF-VAC

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company developing novel, targeted therapies for chronic inflammation, autoimmune diseases and cancer.

Noxopharm's proprietary Sofra™ platform is designed to regulate innate immune signalling with greater precision. Its lead clinical asset, SOF-SKN™, is a topical therapy initially being developed for cutaneous lupus erythematosus, with Phase I completed and further clinical development progressing.

Beyond SOF-SKN, the Sofra platform supports a broader pipeline of internal and externally collaborated programs across inflammatory and autoimmune diseases, RNA therapeutics and oncology.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:
Julian Elliott
M: 0425 840 071
E: julian.elliott@noxopharm.com

Gabriella Hold
The Capital Network
M: 0411 364 382
E: gaby@thecapitalnetwork.com.au

Company Secretary:
Shawn van Boheemen
T: +61 414 903 376
E: shawn.vanboheemen@noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.